United Therapeutics (UTHR) Long-Term Deferred Tax (2009 - 2026)

United Therapeutics has reported Long-Term Deferred Tax for 18 years, with the latest figure at $335.4 million in Q1 2026.

• Quarterly Long-Term Deferred Tax fell 26.54% year-over-year to $335.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $335.4 million (down 26.54% YoY) and the FY2025 annual result came in at $357.7 million, down 21.97% from the prior year.
• Long-Term Deferred Tax retreated to $335.4 million in Q1 2026 per UTHR's latest filing, from $357.7 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $458.4 million in Q4 2024 and troughed at $271.8 million in Q1 2022.
• A 5-year average of $360.3 million and a median of $354.9 million in 2025 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2022 and 2026: Long-Term Deferred Tax gained 25.12% in 2022, then declined 26.54% in 2026.
• Over 5 years, Long-Term Deferred Tax stood at $327.7 million in 2022, then gained by 20.48% to $394.8 million in 2023, then climbed by 16.11% to $458.4 million in 2024, then fell by 21.97% to $357.7 million in 2025, then dropped by 6.23% to $335.4 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $335.4 million, $357.7 million, and $354.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.